Despite the need for further studies to fully elucidate the aforementioned phenomena, adiponectin signaling in PVAT has clearly emerged as a potential therapeutic target for cardiovascular and metabolic disorders. The gene discussed is ADIPOQ; the disease is metabolic disease.